Tvardi Therapeutics
TVRD
95 hedge funds and large institutions have $341M invested in Tvardi Therapeutics in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 28 reducing their positions, and 13 closing their positions.
1,937% more call options, than puts
Call options by funds: $387K | Put options by funds: $19K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
32% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 28
29% more capital invested
Capital invested by funds: $265M → $341M (+$75.6M)
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
3% more funds holding
Funds holding: 92 → 95 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.71M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$6.86M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
+$3.85M |
| 4 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
+$3.76M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$2.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$3.11M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$2.04M |
| 3 |
WSA
Wall Street Associates
Lajolla,
California
|
-$1.81M |
| 4 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
-$1.63M |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$1.23M |
TVRD Hedge Fund Activity: Q4 2015 in Review
95 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2015, worth a combined $341M — up 29% from $265M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TVRD positions and 13 closed out — a net gain of 3 holders — while 37 added to existing stakes and 28 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $7.71M. The largest seller was Renaissance Technologies, cutting an estimated $3.11M.
- 95 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2015, up from 92 in Q3 2015.
- Funds reported $341M of Tvardi Therapeutics stock for Q4 2015, up 29% quarter-over-quarter.
- 16 funds opened new Tvardi Therapeutics positions in Q4 2015 and 13 closed out, a net change of +3 holders.
- The largest Tvardi Therapeutics buyer in Q4 2015 was Point72 Asset Management, an estimated $7.71M added.
- The largest Tvardi Therapeutics seller in Q4 2015 was Renaissance Technologies, an estimated $3.11M sold.
Based on aggregated 13F filings for Q4 2015.